

1 **Determinants of SARS-CoV-2 anti-spike antibody**
2 **levels following BNT162b2 vaccination: cross-**
3 **sectional analysis of 6,000 SIREN study participants**

4
5 Ashley David Otter^{1*}, Silvia D’Arcangelo¹, Heather Whitaker², Jacqueline Hewson¹,
6 Sarah Foulkes², Ana Atti², Michelle Cole², Ezra Linley³, Simon Tonge³, Nipunadi
7 Hettiarachchi², Noshin Sajedi², Davina Calbraith², Chris Norman⁴, Elen de Lacy⁵,
8 Lesley Price^{6,7}, Sally Stewart^{6,7}, Lisa Cromey⁸, Diane Corrigan⁸, **SIREN study**
9 **group†**, Cathy Rowe¹, Colin S Brown⁴, Jasmin Islam⁴, Amanda Semper¹, Susan
10 Hopkins⁹, Victoria Hall^{2,9}, Tim Brooks¹

11

12

13 1 – UK Health Security Agency, Porton Down, SP4 0JG

14 2 – UK Health Security Agency, London, NW9 5EQ

15 3 – UK Health Security Agency, Manchester, M13 9WL

16 4 – Health and Care Research Wales, Cardiff, CF11 9AB

17 5 – Public Health Wales, Cardiff, CF10 4BZ

18 6 – Glasgow Caledonian University, Glasgow, G4 0BA

19 7 – Public Health Scotland, Edinburgh, EH12 9EB

20 8 – Public Health Agency Northern Ireland, Belfast, BT2 8BS

21 9 – UK Health Security Agency, London, SE1 8UG

22

23

24

25 * - **Corresponding author:** Ashley Otter, ashley.otter@ukhsa.gov.uk

26 † - **SIREN study group authors listed within the supplementary material**

27

28

29

30 **Keywords:**

31 BNTb162b2, vaccination, COVID-19, healthcare workers

32 **Abstract:** 250/250

33

34 **Background:** Understanding immunological responses to SARS-CoV-2 vaccinations is
35 integral to the management of SARS-CoV-2. We aimed to investigate determinants of
36 antibody response to the BNT162b2 vaccine.

37

38 **Methods:** A cross-sectional analysis of anti-spike binding antibodies in serum samples from
39 healthcare workers after one or two doses. Post-vaccination interval was restricted to ≥ 21
40 days after dose 1, ≥ 14 days after dose 2. The primary outcome was anti-S titres with
41 explanatory variables dose, previous infection, dosing interval, age, ethnicity, and
42 comorbidities. Multivariable linear regression was also conducted.

43

44 **Results:** Participants (n=5,871) included 3,989 post-dose 1, 1,882 post-dose 2. In SARS-
45 CoV-2 infection naïve, 99.65% seroconverted after dose 1 and >99.9% seroconverted after
46 dose 2. Geometric mean anti-S titre in the naïve cohort was 75.48 Binding Antibody Units/ml
47 after dose 1, 7,049 BAU/ml after dose 2. Anti-S titres were higher in those with previous
48 infection (2,111 BAU/ml post-dose 1, 16,052 BAU/ml post-dose 2), and increased with time
49 between infection and vaccination: 3 months 1,970 (1,506-2,579) vs 9 months; 13,759 (8,097-
50 23,379). Longer dosing intervals increased antibody response post-dose 2: 11-fold higher with
51 a longer interval (>10 weeks) than those with shorter intervals, across all age-groups. Younger
52 participants had higher mean titres (>2.2-fold higher). Multivariable regression modelling
53 corroborated the above associations, and also found higher titres associated with being female
54 or from an ethnic minority but lower titres among immunocompromised participants.

55

56 **Conclusion:** The number of antigen exposures and timing between vaccinations plays a
57 significant role in the magnitude of the post-vaccination antibody response, with implications
58 for long-term protection and post-booster antibody responses.

59

60 Introduction

61 Since its emergence in December 2019, SARS-CoV-2 is the largest respiratory virus
62 pandemic this century, resulting in around 505 million COVID-19 cases and over 6.2 million
63 deaths¹, including 171,396 within the UK². Towards the end of 2020, vaccines against SARS-
64 CoV-2 became available, including the mRNA vaccines (BNT162b2 (Pfizer/BioNTech) and
65 mRNA-1273 (Moderna)), and the chimpanzee adenovirus vectored-vaccine ChAdOx-1 nCoV-
66 19 AZD1222 (Oxford/Astra Zeneca). Whilst single-dose vaccinations have provided some
67 protection from disease in animal models³ and have demonstrated robust antibody
68 responses⁴⁻⁶, data from phase 3 clinical trials of all these vaccines showed highly efficacious
69 protection against severe disease following two vaccine doses, with trial participants
70 demonstrating robust and sustained immunity^{6,7}.

71 On the 2nd December 2020, the MHRA granted temporary authorisation for the use of the
72 Pfizer/BioNTech mRNA vaccine (BNT162b2, Comirnaty) for use within the UK⁸ and the first
73 doses were given on the 8th December 2020⁹. Care home residents, those over 80 years of
74 age and frontline health and social care workers were the primary focus of the initial SARS-
75 CoV-2 vaccine rollout in the UK, with frontline healthcare workers first being offered the
76 BNT162b2 vaccine in December 2020. In line with the evidence from the manufacturer's
77 clinical trials, the vaccine programme initially recommended 3 weeks between the first and
78 second doses of BNT162b2⁷. Faced with a finite supply of vaccines, in January 2021 the Joint
79 Committee on Vaccination and Immunization (JCVI) recommended extending the interval
80 between first and second dose to up to 12 weeks for both the Pfizer and Oxford Astra/Zeneca
81 vaccines, in order to maximise the number of people receiving a first dose and therefore some
82 level of protection against SARS-CoV-2^{10,11}.

83 As of March 2022, 86.2% of the UK population aged over 12 years had received at least two
84 doses, whilst 92.1% had been given at least one dose of a SARS-CoV-2 vaccine¹². With
85 increases in disease prevalence and the spread of variants of concern (e.g. Delta and
86 Omicron), the vaccines have shown their capability to prevent and protect against severe
87 SARS-CoV-2 disease, but further work is ongoing to understand durability of the immune
88 response, correlates of protection and why some individuals develop COVID-19 even when
89 double vaccinated.

90 The SARS-CoV-2 Infection and Reinfection Evaluation (SIREN) is a longitudinal study of over
91 44,000 healthcare workers across the UK¹³⁻¹⁵. Its initial focus was to assess the impact of
92 infection/reinfection on immunity, but it has since been applied to study vaccination responses
93 in detail. The aim of this paper is to analyse the levels of anti-spike binding antibodies and
94 after COVID-19 vaccination and/or SARS-CoV-2 infection, stratified by age, previous infection,

95 gender, health conditions, vaccine dose, timing between sample collection and vaccination,
96 and dosing interval.

97 **Methods**

98

99 **Study design and setting**

100 For this cross-sectional analysis, a convenience sample was drawn from the cohort of
101 healthcare workers enrolled within the SARS-CoV-2 Infection and Reinfection Evaluation
102 (SIREN) study^{13–15}. Inclusion and exclusion criteria for the main analysis can be found in the
103 supplementary material (**Supplementary figure 1**). In brief, eligible participants had submitted
104 an enrolment sample (baseline sample) that had been tested using the Roche Elecsys
105 quantitative SARS-CoV-2 anti-spike (S) and semi-quantitative anti-nucleocapsid (N) antibody
106 assays and submitted this after their first or second COVID-19 vaccination, or were anti-N
107 positive and submitted the sample before vaccination. Only participants receiving 1 or 2 doses
108 of BNT162b2 were included, with vaccines other than BNT162b2 or unknown vaccines
109 excluded due to low vaccination numbers (e.g. ChAdOx-1, mRNA-1273). To prevent bias in
110 the data from participants still mounting an antibody response at the time of sampling, only
111 those participants that gave a baseline sample ≥ 21 days post dose 1 or post-infection, and
112 those ≥ 14 days post dose 2 were included in the final analysis.

113

114 **Data sources**

115 Vaccination data (manufacturer, dates) were obtained via linkage on personal identifiers from
116 national COVID-19 vaccination registries and directly from participants in their study
117 questionnaires. Site test results reported into national laboratory surveillance systems (in
118 England the Second-Generation Surveillance System (SGSS), with equivalent data securely
119 transferred from Northern Ireland, Wales and Scotland) were linked to individuals' personal
120 information provided in the enrolment questionnaire, with testing data updated daily and
121 captured in a SQL SIREN Database. Serology results from standardised antibody testing at
122 the UKHSA SARS-CoV-2 Serosurveillance laboratory were captured in the SIREN database
123 through linkage on unique identifiers. Data from participants with baseline serum samples with
124 confirmatory antibody test results were extracted from the SIREN SQL database.

125 **Outcomes**

126 The primary outcome was anti-S titre using the Roche Elecsys anti-spike (ACOV2 S) assay
127 which specifically targets anti-RBD antibodies, as described elsewhere^{4,16}. Samples were
128 considered positive for anti-nucleocapsid and anti-spike antibodies if the results were ≥ 1.0
129 COI and ≥ 0.8 U/ml, respectively. The Roche Elecsys anti-nucleocapsid assay is semi-

130 quantitative, as described elsewhere¹⁷, with the presence of anti-nucleocapsid antibodies
131 used as a proxy for probable previous infection in the absence of a previous PCR positive.
132 The Roche anti-spike assay is quantitative, producing results between 0.4 U/ml and 225,000
133 U/ml, with automatic dilutions performed to achieve sample results within the quantitative
134 range (0.4 to 250 U/ml). The Roche anti-spike assay has been fully calibrated to the NIBSC
135 first WHO International SARS-CoV-2 immunoglobulin standard (NIBSC code 20/136),
136 enabling reporting in binding antibody units (BAU) per ml (BAU/ml), with all analyses here
137 presented as BAU/ml¹⁸.

138

139 **Explanatory variables**

140 Participants were characterised according to their previous infection status: 'naïve' (anti-
141 nucleocapsid negative at baseline and no linked PCR positive results), 'previous infection with
142 PCR+' (anti-N positive at baseline and linked previous SARS-CoV-2 PCR positive result),
143 'previous infection without PCR+' (no known previous SARS-CoV-2 PCR positive date but
144 presence of anti-nucleocapsid antibodies). Samples from cohorts of participants pre-
145 vaccination and post-vaccination were used to compare post-vaccination and post-infection
146 antibody titres.

147 Outcomes were stratified by dosing interval, age, gender, ethnicity and comorbidities. For
148 analysis on existing health conditions, participants were classified into three categories based
149 on data provided within their enrolment questionnaire. Specific health conditions were
150 categorised: immunosuppression (participants with immune system cancer, rheumatology
151 disease, transplant recipients, those with spleen conditions or other autoimmune conditions
152 not listed here), chronic respiratory disease (asthma, chronic obstructive pulmonary disease,
153 or other chronic respiratory diseases), and chronic non-respiratory diseases (diabetes,
154 obesity, chronic-neurological disease, dementia, other cancers, chronic heart disease, chronic
155 kidney disease, liver disease and HIV).

156 **Statistical analysis**

157 All statistics were performed on log transformed anti-spike antibody values (in BAU/ml), unless
158 otherwise stated, using R (version 4.0.2), with regression analysis performed in STATA
159 (version 14.2). Mean antibody titres are reported as geometric means. Two-sample t-tests
160 were used for comparisons between groups. Normal error multivariable linear regression
161 models were fitted to log antibody levels (separate models for 28+ days post dose 1 and 21+
162 days post dose 2), including covariates such as days since dose, age group, sex, ethnicity,
163 existing health conditions and for dose 2 only, dosing schedule group. Regression coefficients
164 were exponentiated for interpretation as adjusted geometric mean ratios. The interval in days

165 between vaccine dose and the baseline SIREN sample was modelled as log linear (i.e.
166 exponential decay on the original scale). All other covariates were categorical.

167

168 **Ethics**

169 Ethics approval was granted on 22 May 2020 under IRAS ID 284460, Berkshire Research

170 Ethics Committee Approval by HRA and Health and Care Research Wales.

171

172 **Results**

173 A total of 13,002 participants were included in this analysis, 5,871 post vaccination; ≥ 21 days
174 post-dose 1 (n=3,989) and ≥ 14 days post-dose 2 (n=1,882), and 7,131 participants who
175 provided baseline samples prior to vaccination and had evidence of previous infection. Most
176 participants were female (82.25%) and of white ethnicity (86.94%) and were distributed across
177 the different regions of England (n=9,007, 69.27%) as well as Wales (n=669, 5.15%), Scotland
178 (n=2,860, 22.00%), and Northern Ireland (n=466, 3.58%).

179

180 Cohort assignment was as follows: naïve cohort (post-dose 1: n=2,863; post-dose 2: n=1,523);
181 previous infection with PCR+ (post-dose 1: n=571; post-dose 2; n=165); previous infection
182 without PCR+ (post-dose 1: n=555; post-dose 2, n=194). Further classification and numbers
183 per infection cohort, gender and ethnicity can be found in **Table 1** (with breakdown further
184 shown in supplementary table 1). Within the pre-vaccination cohort, participants were similarly
185 assigned previous infection with PCR+ (n=1,990) or previous infection without PCR+
186 (n=5,141).

187

188 In the naïve cohort 2,853 participants (99.65%) seroconverted after dose 1, with detectable
189 anti-spike antibodies (≥ 0.8 BAU/ml). Of the 10 participants that did not seroconvert post-dose
190 1 (0.35%), the median age was 51 years (Range 40 – 65, IQR 44.5 – 56.75) and a median of
191 41 days between first vaccination and sample date (Range 24 – 71, IQR 36.25 – 46.75). When
192 analysing the sera of participants ≥ 14 days post-dose 2, 1,522/1,523 participants
193 seroconverted (99.93%), with only one participant aged in their 50s not seroconverting within
194 29 days between dose 2 and the sample date.

195

196 **Previously infected individuals mount a significantly higher anti-spike antibody** 197 **response post-dose 1 and post-dose 2**

198 Geometric mean levels of anti-spike binding antibody titres post-dose 1 from all naïve
199 participants (n=2,863) were 75.48 BAU/ml (95% CI: 72.26 – 78.84), whereas significantly
200 higher titres were measured in those with previous infection with PCR+ (n=571, 2,111 BAU/ml
201 (1,782 – 2,501); $p < 0.0001$) and previous infections without PCR+ (n=555, 7,077 BAU/ml
202 (6,248 – 8,016); ($p < 0.0001$)) (Supplementary Figure 2).

203

204 Geometric mean titres post-dose 2 from all naïve participants (n=1,523) were 7,050 BAU/ml
205 (6,634 – 7,491), whilst those with previous infection with PCR+ (n=165) and previous infection
206 without PCR+ (n=194) were significantly higher at 16,052 BAU/ml (14,071 – 18,312,

207 $p < 0.0001$) and 17,759 BAU/ml, respectively (15,595 – 20,222, $p < 0.0001$) (Supplementary
208 Figure 2).

209

210 Previous infection results in comparable antibody titres to 1 vaccine dose. In those with
211 previous infection with PCR+, geometric mean antibody titres post-infection were 96.99
212 BAU/ml (89.53 – 105) whilst those with previous infection without PCR+ had a geometric mean
213 titre of 81.20 (77.50 – 85.07), which is highly similar to the naïve group receiving their first
214 dose, with a geometric mean titre of 75.48 (72.26 – 78.84).

215

216 **Age and dosing interval have significant effects on post-vaccination antibody titres**

217 Naïve older participants had significantly lower antibody responses post-dose 1 than younger
218 HCWs (**Figure 2**); there was a ~2-fold decrease between the 25-34 years (115 BAU/ml, 95%
219 CI 105 - 126) and >54 years (55.51 BAU/ml, 95% CI 50.7 - 60.78) age groups (2.03, 95% CI
220 1.78-2.32). Similarly, a ~2.3-fold decrease was observed between the 25-34 (12,288 BAU/ml;
221 95% CI 9,140 – 16,520) and >54 years (5,367 BAU/ml, 95% CI 4,691 – 6,140) age groups
222 post-dose 2 (1.63, 95% CI 1.34-1.98). In contrast, those with previous infection, showed no
223 significant differences between any of the age groups post-dose 1 or post-dose 2 (Figure 1).

224 The geometric mean antibody titres increased with longer intervals between doses, with a 9-
225 fold increase after an interval of >10 weeks compared with >2 and <4 weeks, with this trend
226 consistent across all age groups (Table 2). In general, younger participants had significantly
227 higher antibody responses than older participants with the same vaccine interval, with the
228 exception of the >2 and <4-week dose interval (due to low numbers in the <25 and 25-34 age
229 groups) (Table 2). Thus, participants aged >54 years with a dosing interval of >2 and <4 weeks
230 had a geometric mean antibody titre of 1,303 BAU/ml ($n = 25$, 95% CI 713.28 - 2382), whereas
231 those aged <25 years with a >10 week dosing interval had a geometric mean antibody titre of
232 21,472 BAU/ml ($n = 10$, 95% CI 14,435 – 31,940), a ~16.5 fold difference (Table 2). Antibody
233 titres for each of the dosing interval groups were also analysed in relation to the time elapsed
234 between vaccination and sample date, to prevent the data being skewed by sampling bias
235 (Supplementary Table 3 and Supplementary figure 4). Irrespective of whether participants
236 provided a baseline sample 4-5 weeks, 6-7 weeks or 8-9 weeks after their second dose, the
237 significant difference between >2 and <4 weeks and >10 weeks dosing intervals remained,
238 highlighting that the observed difference in antibody titres was due to the dosing interval and
239 not due to sample collection bias.

240

241 **Increasing time between previous infection and dose 1 results in increased antibody** 242 **titres**

243 Those with previous infection without PCR+ had a significantly higher geometric mean
244 ($p < 0.0001$) anti-spike antibody level post-dose 1 (7,077 BAU/ml) than those with previous
245 infection with PCR+ (2,111 BAU/ml). When further stratifying the previous infection with PCR+
246 group by time between infection (median; 101 days) and vaccine dose 1, in general, increasing
247 antibody titres were seen with increasing months after infection, up to 6 months and plateauing
248 (3 months; 1,971 (1,506-2,579) vs 9 months; 13,759 (8,098-23,379), $p < 0.0001$, **Figure3A**).
249 No increase in antibody titre was observed with increasing months between infection and dose
250 2 (**Figure3C**).

251


252 **Multivariable regression models: the impacts of days since dose, age, gender,** 253 **ethnicity, and prior health conditions on post-vaccination antibody levels**

254 The decline in antibody levels following dose 1 was shallow, with a long half-life of 157.6 days
255 (95% CI 92.1 - 546.2). Following dose 2 the decline was steeper, with a half-life of 45 days
256 (95% CI 34.3 - 67.2). Adjusted geometric mean ratio of responses is shown (**Figure 4**,
257 Supplementary table 2). Age was associated with antibody titres, with significantly higher titres
258 in younger age groups. Female participants were found to have slightly higher antibody titres
259 post-dose 1 ($p < 0.001$), but post-dose 2, this significance was not seen ($p = 0.151$).
260 Conversely, ethnic minority participants displayed no significant difference in antibody
261 responses post-dose 1 ($p = 0.147$), however, they did show a significantly higher antibody
262 response post-dose 2 ($p = 0.024$). No significant difference was observed between any of these
263 groups post-dose 2 in those previously infected, with PCR+ or without PCR+.

264


265 In naïve, immunosuppressed participants, antibody titres post-dose 1 and post-dose 2 were
266 significantly lower than in participants with no immunosuppression (post-dose 1; $p = 0.001$,
267 post-dose 2 = $p < 0.001$) However no significant difference was seen in those with previous
268 infection post-dose 2 ($p = 0.563$). Naïve participants with chronic non-respiratory diseases had
269 a significantly lower antibody titre post-dose 1 ($p = 0.005$), but no significant difference was
270 observed in participants post-dose 2 ($p = 0.994$). Chronic respiratory disease had no impact on
271 post-dose 1 ($p = 0.566$) or post-dose 2 ($p = 0.512$) antibody titres, and similarly no difference
272 was observed post-dose 2 in previously infected participants ($p = 0.830$).

273




274

275 **Figure 1: Antibody levels post-dose 1 (left), post-dose 2 (middle) and post-infection (right), split by cohort and age group.** Naive - those
 276 with no known previous COVID-19 disease (no PCR confirmation or anti-nucleocapsid antibodies at baseline). Previous infection with PCR+ –
 277 those with a confirmed PCR positive. Previous infection without PCR+, those with no known PCR positive date, but presence of anti-nucleocapsid
 278 antibodies.




279

280 **Figure 2: Geometric mean anti-spike antibody levels (BAU/ml) of naïve participants post**
281 **dose 2 split according to dosing interval and age.** Mean BAU/ml increases with dosing
282 interval but decreases with age. Only 1 participant was available within the <25 age category
283 and 2-3-week interval group. The circle diameters correspond to the number of participants
284 for each age group at each dosing interval. Error bars shown are 95% CI.



285

286 **Figure 3: Post-dose 1 and post-dose 2 antibody titres in participants with previous infection (with history of PCR+), stratified by the**
 287 **interval (in months) between infection (PCR positive date) and vaccine dose 1 date (A) and vaccine dose 2 date (C). Mean post-dose 1**
 288 **titres according to a participant's exposure status post-dose 1 (B) and post-dose 2 (D).** Data shows a general trend of increasing post-
 289 dose 1 antibody titres up to 6 months between infection and dose 1. Only participants that provided a baseline sample ≥ 21 days and < 71 days
 290 (10 weeks) after dose 1, and those that provided a baseline sample ≥ 14 days and < 71 days (10 weeks) after dose 2 were included. PI; previous
 291 infection, w/o; without.



292

293

294 **Figure 4: Multivariable regression analysis on anti-spike antibody levels, according to**
 295 **age group, dosing interval group, ethnicity, and gender, and also adjusted for days**
 296 **since dose.** Data includes those post-dose-1 (≥ 28 days) and post-dose 2 (≥ 21 days). Age
 297 and dosing interval significantly affect antibody titres. Previous infection was grouped based
 298 on history of PCR+ or presence of anti-nucleocapsid antibodies. Due to low numbers, previous
 299 infected individuals with 1 vaccine dose were not included in this analysis

300 **Table 1: Anti-spike antibody titres for the post-vaccination SIREN cohort.** All data is split according to prior infection status (naïve, previous infection without PCR+, or
 301 previous infection with PCR+) as well as gender, ethnicity and age. Data are presented as geometric means of the Roche S values (BAU/ml) with 95% CIs. Those categories
 302 with less than 5 participants were removed due to high statistical variance.

		n=	Post Dose 1 (>=21 days)	n=	Post Dose 2 (>=14 days)
Naive		2863	75.48 (72.26 - 78.84)	1523	7,049.76 (6634.3 - 7491.25)
Gender	Male	454	65.76 (58.62 - 73.76)	271	6,447.43 (5574.51 - 7457.04)
	Female	2406	77.48 (73.92 - 81.21)	1250	7,172.98 (6708.55 - 7669.55)
	Other/Prefer not to say	3	N/A	2	N/A
Ethnicity	White	2657	75.12 (71.78 - 78.62)	1376	7,111.25 (6664.14 - 7588.35)
	BAME	204	80.26 (68.89 - 93.5)	146	6,496.29 (5505.18 - 7665.82)
	Other/Prefer not to say	2	N/A	1	N/A
Age	<25	76	125.07 (108.12 - 144.66)	33	12,287.78 (9140.08 - 16519.5)
	25-34	548	114.91 (105.16 - 125.57)	238	9,696.5 (8389.91 - 11206.56)
	35-44	736	80.33 (73.47 - 87.83)	397	8,170.3 (7343.88 - 9089.71)
	45-54	831	66.27 (61.22 - 71.75)	495	6,313.87 (5662.17 - 7040.59)
	>54	672	55.51 (50.7 - 60.78)	360	5,366.81 (4690.7 - 6140.38)
Previous Infection (Without PCR+, Anti-nucleocapsid positive)		555	7,076.57 (6247.59 - 8015.54)	194	17,758.50 (15594.98 - 20222.18)
Gender	Male	104	5,768.25 (4053.02 - 8209.36)	43	20,738.96 (16574.49 - 25949.79)
	Female	451	7,418.14 (6511.7 - 8450.76)	151	16,990.98 (14555.7 - 19833.7)
	Other/Prefer not to say	0	N/A	0	N/A
Ethnicity	White	487	6,964.52 (6067.97 - 7993.53)	169	17,666.38 (15311.83 - 20383)
	BAME	66	8,103.88 (6287.82 - 10444.45)	25	18,393.99 (13517.06 - 25030.5)
	Other/Prefer not to say	2	N/A	0	N/A
Age	<25	27	10,232.65 (6541.52 - 16006.54)	8	22,227.7 (15374.06 - 32136.63)
	25-34	110	6,096.39 (4511.9 - 8237.32)	39	16,826.71 (13211.03 - 21431.95)
	35-44	136	5,662.27 (4459.85 - 7188.89)	40	18,400.62 (14680.29 - 23063.76)
	45-54	138	7,319.52 (5723.73 - 9360.23)	70	17,144.67 (12938.13 - 22718.88)

	>54	144	8,844.16 (6841.99 - 11432.22)	37	18,417.3 (14060.62 - 24123.89)
	Previous Infection (With PCR+)	571	2,111.08 (1781.99 - 2500.95)	165	16,052.39 (14071.49 - 18312.15)
Gender	Male	82	2,200.72 (1395.27 - 3471.16)	40	18,734.58 (14180.51 - 24751.18)
	Female	487	2,108.03 (1754.42 - 2532.9)	125	15,277.99 (13143.93 - 17758.55)
	Other/Prefer not to say	2	N/A	0	N/A
Ethnicity	White	511	2,066.43 (1725.08 - 2475.32)	147	15,715.86 (13643.01 - 18103.65)
	BAME	59	2,409.72 (1465.83 - 3961.38)	18	19,084.72 (13066.95 - 27873.89)
	Other/Prefer not to say	1	N/A	0	N/A
Age	<25	12	1,913.14 (668.94 - 5471.5)	7	17,550.23 (13979.59 - 22032.88)
	25-34	108	2,410.56 (1691.59 - 3435.1)	31	14,452.38 (10842.22 - 19264.62)
	35-44	151	1,714.91 (1231.82 - 2387.46)	47	16,968.73 (13271.93 - 21695.26)
	45-54	182	1,979.32 (1460.01 - 2683.34)	46	15,309.26 (11948.24 - 19615.72)
	>54	118	2,721.44 (1808.12 - 4096.1)	34	17,126.27 (11820.96 - 24812.63)

304 **Table 2: Anti-spike antibody titres (BAU/ml) of naive participants post-second vaccine dose, split according to age.** Data are presented as geometric means, with 95%
 305 CIs. All groups exhibit higher anti-spike antibody titres with increasing interval, whilst decreasing titres are found with age group in all dosing intervals. GMC: Geometric mean
 306 (BAU/ml).

		Dose interval (time between 1 st dose and 2 nd dose)							
		>2 and <4 weeks		>4 and <7 weeks		>7 and <10 weeks		>10 weeks	
Age group		n=	GMC (95% CI)	n=	GMC (95% CI)	n=	GMC (95% CI)	n=	GMC (95% CI)
	<25	1	1,540 (1540 - 1540)	9	7,320.66 (4076.85 - 13145.47)	13	13,430.99 (9117.29 - 19785.62)	10	21,472.12 (14435.06 - 31939.72)
	25-34	14	1,541.01 (1089.67 - 2179.29)	39	4,261.08 (2962.14 - 6129.62)	52	11,100 (8010.84 - 15380.4)	133	14,205.57 (12350.18 - 16339.69)
	35-44	19	1,626.8 (1196.19 - 2212.42)	76	3,648.89 (3003.64 - 4432.75)	85	8,994.43 (7515.83 - 10763.92)	217	12,018.95 (10531.43 - 13716.58)
	45-54	34	993.47 (778.96 - 1267.07)	101	2,584.21 (2071.11 - 3224.42)	103	6,267.91 (4869.24 - 8068.36)	257	11,489.2 (10455.48 - 12625.12)
	>54	25	1,303.47 (713.28 - 2382)	87	2,368.84 (1893.59 - 2963.37)	75	6,984.68 (5632.33 - 8661.74)	173	8,862.21 (7428 - 10573.33)

307

308

309

310 Discussion

311

312 With data from 5,871 well-characterised participants after vaccination and 7,131 after
313 infection, and all tested on the same anti-spike and anti-nucleocapsid assays, this dataset has
314 provided a highly robust, cross-sectional analysis of determinants of the antibody response
315 following vaccination. As this study used a fully quantitative anti-RBD assay reporting in
316 BAU/ml relative to the 1st WHO international SAR-CoV-2 immunoglobulin standard¹⁹, this
317 enables meaningful comparison of post-vaccination responses in different cohorts and across
318 diverse studies. Our data now offers a benchmark against which to compare results by age
319 (and additional variables) across diverse post-vaccination studies, with comparisons to other
320 major manufacturers available through the HARMONY study. We have shown that antibody
321 response increases with repeated antigenic exposure, with participants with three antigen
322 exposures (infection and then two vaccine doses) having the highest anti-S titres. We
323 observed similar anti-S responses in those with a single antigen exposure, irrespective of
324 whether this was from infection or vaccination. Anti-S titres were much higher after two vaccine
325 doses than infection alone. Timing of second antigen exposure impacted antibody responses
326 in our participants, with longer intervals between successive vaccine doses, or first vaccine
327 dose after infection, associated with an increased antibody response as demonstrated by
328 others^{6,20-23}. We also found associations with age and immunosuppression, with higher anti-
329 S titres in younger participants and lower titres in those with immunosuppression.

330

331 Other studies have also found higher anti-S titres following two antigen exposures, whether
332 vaccination alone or infection and then a single vaccine dose^{4,24-26}, but few have shown that
333 those with prior infection continue to have higher titres than double-vaccinated infection-naïve
334 individuals, suggesting that those with prior infection still benefit from vaccination. This finding
335 of incremental increases in anti-S titre with repeated antigen exposures but then subsequent
336 evidence of waning (and diminished protection from infection six months after vaccination)
337 informed the decision to introduce booster doses in the UK and globally. A greater immune
338 response following longer intervals between vaccine doses has also been reported by others,
339 including T-cell and antibody responses^{6,21-23}. Together the evidence supports the decision
340 made in the UK, and subsequently other countries, to delay the interval between doses^{27,28}.
341 Our data has also shown a similar effect, with higher anti-S titres with extended intervals
342 between infection and vaccination. It is important to recognise however that within the SIREN
343 cohort we have not observed a corresponding difference in protection against SARS-CoV-2
344 infection associated with timing of dosing interval¹³. Our data also adds to the literature on
345 lower vaccine responses in older age groups²⁹⁻³² and individuals with immunosuppression^{33,34},
346 which should inform continued targeted interventions for these groups. Furthermore, with

347 participants having diverse infection history (Wuhan, Alpha, Delta) we are now looking at the
348 role of prior infection and antigenic imprinting on vaccination responses³⁵.

349

350 Whilst this analysis involved a large population, enabling us to investigate several explanatory
351 and control for important confounders, as a cross-sectional design, we have not followed-up
352 individuals longitudinally. This means we are unable to assess the durability of antibody
353 response in this analysis. Our data is also limited to anti-S titres and does not provide data on
354 neutralising antibody response³⁶ or T-cells responses²² as others have shown. It is also
355 important to recognise that we were unable to investigate important factors such as ethnicity
356 and vaccine type in this analysis given the SIREN cohort is predominately of white ethnicity
357 and received the BNT162b2 vaccine. A longitudinal analysis including neutralising antibody
358 testing is underway investigating responses to booster vaccine doses.

359

360 The SIREN cohort continues to provide insights into vaccine effectiveness, vaccine
361 responses, reinfections and now vaccination breakthrough infections. With the waning of
362 immunity and increasing vaccine breakthroughs, this cohort will play an essential part in
363 determining why patients develop vaccine breakthrough infections and determining any
364 potential correlates of protection.

365

366 **Conclusion**

367 The SIREN cohort continues to provide insights into vaccine effectiveness, vaccine
368 responses, reinfections and now vaccination breakthrough infections. With the waning of
369 immunity and increasing vaccine breakthroughs, this cohort will play an essential part in
370 determining why patients develop vaccine breakthrough infections and determining any
371 potential correlates of protection.

372

373 **Data availability statement**

374 Annotated code for this analysis is available at: ([https://github.com/SIREN-study/SARS-CoV-](https://github.com/SIREN-study/SARS-CoV-2-Immunity)
375 2-Immunity). The metadata for this analysis will be available to researchers through the Health
376 Data Research UK CO-CONNECT platform and available for secondary analysis.

377

378 **Acknowledgments**

379 We thank all SIREN participants for enrolling within the SIREN study and continuing to provide
380 samples. We also thank all staff within the NHS that enable SIREN to operate.

381 Additionally, we thank the staff and students at UKHSA Porton Down that conducted the
382 sample receipt and testing of baseline SIREN samples.

383

384 **Author contributions**

385 ADO, VH, SH, HW, TB and AS conceptualised this analysis. ADO wrote the initial manuscript,
386 with input from AS, VH, SF, SH, TB, HW, JH, SD'A and AA. ADO, SD'A, JH, CR, AS and TB
387 oversaw the serological testing. EL and ST are responsible for sample collation, shipping and
388 archiving, with support from JH. HW supported statistical analysis. VH and SH design and
389 lead on the SIREN study. MC, EL, ST, AT-K, NH, NS, DC, IM, CT, CSB and JI support sample
390 receipt, movement of samples and general SIREN operations.

391

392 **Competing interests**

393 The authors declare no competing interests.

394

395 **Ethics**

396 This study was registered, number ISRCTN11041050, and received approval from the
397 Berkshire Research Ethics Committee on 22 May 2020

398

399 **Funding**

400 The study is funded by the Department for Health and Social Care and UKHSA (formerly
401 PHE), with contributions from the governments of Northern Ireland, Scotland and Wales.
402 Funding was also provided by The National Institute for Health Research (NIHR) as an Urgent

403 Public Health Priority Study and through the Health Protection Research Units. The study was
404 also awarded grant funding from the Medical Research Council (Grant title: Investigation of
405 proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker
406 cohorts: SIREN consortium & PITCH Plus Pathway).

407

408 **Grants**

409 Grant funding awarded by the MRC in 2021 for the investigation of vaccine breakthroughs
410 within SIREN and the SIREN consortium (Grant number: MR/W02067X/1)

411 References

412

- 413 1. John Hopkins University. COVID-19 Dashboard. (2022).
- 414 2. GOV.UK. UK Coronavirus Dashboard. (2022).
- 415 3. Huang, Q. *et al.* A single-dose mRNA vaccine provides a long-term protection for
416 hACE2 transgenic mice from SARS-CoV-2. *Nat. Commun.* **12**, 1–10 (2021).
- 417 4. Manisty, C. *et al.* Antibody response to first BNT162b2 dose in previously SARS-CoV-
418 2-infected individuals. *Lancet* (2021). doi:10.1016/S0140-6736(21)00501-8
- 419 5. Bradley, T. *et al.* Antibody Responses after a Single Dose of SARS-CoV-2 mRNA
420 Vaccine. *N. Engl. J. Med.* **384**, 1959–1961 (2021).
- 421 6. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the
422 booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)
423 vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–891 (2021).
- 424 7. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N.*
425 *Engl. J. Med.* **383**, 2603–2615 (2020).
- 426 8. Medicines & Healthcare products Regulatory Agency (MHRA). *Vaccine BNT162b2 –*
427 *CONDITIONS OF AUTHORISATION UNDER REGULATION 174.* (2021).
- 428 9. Medicines & Healthcare products Regulatory Agency (MHRA). Public Assessment
429 Report Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2
430 concentrate for solution for injection Department of Health and Social Care (DHSC)
431 Pfizer Limited & BioNTech Manufacturing GmbH. **2**, 1–74 (2020).
- 432 10. Public Health England. *Annex A: Report to JCVI on estimated efficacy of a single*
433 *dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of*
434 *ChAdOx1 vaccine (AZD1222).* (2020).
- 435 11. Public Health England. JCVI issues interim advice on COVID-19 booster vaccination.
436 (2021). Available at: [https://www.gov.uk/government/news/jcvi-issues-advice-on-the-](https://www.gov.uk/government/news/jcvi-issues-advice-on-the-astrazeneca-covid-19-vaccine)
437 [astrazeneca-covid-19-vaccine](https://www.gov.uk/government/news/jcvi-issues-advice-on-the-astrazeneca-covid-19-vaccine). (Accessed: 20th October 2021)
- 438 12. Gov.uk. GOV.UK Coronavirus (COVID-19) in the UK. (2021). Available at:
439 coronavirus.data.gov.uk.
- 440 13. Hall, V. *et al.* Protection against SARS-CoV-2 after Covid-19 Vaccination and
441 Previous Infection. *N. Engl. J. Med.* (2022). doi:10.1056/nejmoa2118691
- 442 14. Hall, V. J. *et al.* COVID-19 vaccine coverage in health-care workers in England and
443 effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective,
444 multicentre, cohort study. *Lancet (London, England)* 1725–1735 (2021).
445 doi:10.1016/S0140-6736(21)00790-X
- 446 15. Hall, V. J. *et al.* SARS-CoV-2 infection rates of antibody-positive compared with

- 447 antibody-negative health-care workers in England: a large, multicentre, prospective
448 cohort study (SIREN). *Lancet* **397**, 1459–1469 (2021).
- 449 16. Parry, H. *et al.* Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after
450 extended-interval homologous dual vaccination in older people. *Immun. Ageing* **18**, 1–
451 8 (2021).
- 452 17. Manisty, C. *et al.* Time series analysis and mechanistic modelling of heterogeneity
453 and sero-reversion in antibody responses to mild SARS-CoV-2 infection.
454 *EBioMedicine* **65**, 103259 (2021).
- 455 18. Elecsys® Anti-SARS-CoV-2 S. Available at:
456 [https://diagnostics.roche.com/global/en/products/params/electsys-anti-sars-cov-2-](https://diagnostics.roche.com/global/en/products/params/electsys-anti-sars-cov-2-s.html)
457 [s.html](https://diagnostics.roche.com/global/en/products/params/electsys-anti-sars-cov-2-s.html). (Accessed: 12th February 2021)
- 458 19. Kristiansen, P. A. *et al.* WHO International Standard for anti-SARS-CoV-2
459 immunoglobulin. *Lancet* **397**, 1347–1348 (2021).
- 460 20. Tauzin, A. *et al.* Strong humoral immune responses against SARS-CoV-2 Spike after
461 BNT162b2 mRNA vaccination with a sixteen-week interval between doses. *medRxiv*
462 2021.09.17.21263532 (2021). doi:10.1101/2021.09.17.21263532
- 463 21. Parry, H. *et al.* Extended interval BNT162b2 vaccination enhances peak antibody
464 generation in older people. *medRxiv* 2021.05.15.21257017 (2021).
465 doi:10.1101/2021.05.15.21257017
- 466 22. Payne, R. P. *et al.* Immunogenicity of standard and extended dosing intervals of
467 BNT162b2 mRNA vaccine. *Cell* (2021). doi:10.1016/j.cell.2021.10.011
- 468 23. Angyal, A. *et al.* Articles T-cell and antibody responses to first BNT162b2 vaccine
469 dose in previously infected and SARS-CoV-2-naive UK health-care workers: a
470 multicentre prospective cohort study. *The Lancet Microbe* (2021). doi:10.1016/S2666-
471 5247(21)00275-5
- 472 24. Tré-Hardy, M. *et al.* Reactogenicity, safety and antibody response, after one and two
473 doses of mRNA-1273 in seronegative and seropositive healthcare workers. *Journal of*
474 *Infection* **83**, 237–279 (2021).
- 475 25. Prendecki, M. *et al.* Effect of previous SARS-CoV-2 infection on humoral and T-cell
476 responses to single-dose BNT162b2 vaccine. *The Lancet* **397**, 1178–1181 (2021).
- 477 26. Krammer, F. *et al.* Antibody Responses in Seropositive Persons after a Single Dose
478 of SARS-CoV-2 mRNA Vaccine. *N. Engl. J. Med.* **384**, 1372–1374 (2021).
- 479 27. Joint Committee on Vaccinations and Immunisations. Optimising the COVID-19
480 vaccination programme for maximum short-term impact. Updated January 26, 2021.
481 *January 26* 1–5 (2021).
- 482 28. Center for Disease Control and Prevention. Use of COVID-19 Vaccines in the United
483 States. *Febr. 22* 1–3 (2022).

- 484 29. Wei, J. *et al.* Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the
485 general population of the United Kingdom. *Nat. Microbiol.* **6**, 1140–1149 (2021).
- 486 30. Collier, D. A. *et al.* Age-related immune response heterogeneity to SARS-CoV-2
487 vaccine BNT162b2. *Nature* **596**, 417–422 (2021).
- 488 31. Subbarao, S. *et al.* Robust antibody responses in 70-80-year-olds 3 weeks after the
489 first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom,
490 January to February 2021. *Eurosurveillance* **26**, 1–6 (2021).
- 491 32. Eyre, D. W. *et al.* Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech
492 and Oxford–AstraZeneca vaccines by previous infection status. *Clin. Microbiol. Infect.*
493 **27**, 1516.e7-1516.e14 (2021).
- 494 33. Kearns, P. *et al.* Examining the Immunological Effects of COVID-19 Vaccination in
495 Patients with Conditions Potentially Leading to Diminished Immune Response
496 Capacity – The OCTAVE Trial. *SSRN Electron. J.* 1–25 (2021).
497 doi:10.2139/ssrn.3910058
- 498 34. Parry, H. *et al.* Antibody responses after first and second Covid-19 vaccination in
499 patients with chronic lymphocytic leukaemia. *Blood Cancer J.* **11**, 4–11 (2021).
- 500 35. Reynolds, C. J. *et al.* Heterologous infection and vaccination shapes immunity against
501 SARS-CoV-2 variants. *Science (80-.)*. (2021). doi:10.1126/science.abm0811
- 502 36. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19
503 Vaccine over 6 Months. *N. Engl. J. Med.* 1–11 (2021). doi:10.1056/NEJMoa2114583
504
505